弥漫相关光谱无创监测心源性休克及VA-ECMO支持期间外周灌注的实验研究
研究在7只雄性比格犬(中位体重10.1 kg)中通过冠状动脉结扎诱导心源性休克后诱发心室颤动,5分钟后启动VA-ECMO(80-100 mL·kg⁻¹·min⁻¹)并维持90分钟非搏动血流。随后将VA-ECMO流量从100降至30 mL·kg⁻¹·min⁻¹,并用血管收缩药将平均动脉压升至≥65 mmHg。结果显示,室颤期间灌注指数无法测量而DCS-derived血流指数(BFI)快速降至近零;VA-ECMO启动恢复MAP和混合静脉血氧饱和度,BFI与皮肤血流逐渐恢复;降低ECMO流量使MAP和BFI下降,血管收缩药升高MAP但未能改善BFI。作者认为DCS可能有助于早期识别微循环障碍并优化心源性休克治疗。
要点
- 在7只比格犬心源性休克模型中,室颤期间灌注指数无法测量,而DCS衍生的BFI快速降至近零,可在非搏动条件下检测外周血流丧失。
- VA-ECMO启动后MAP和混合静脉血氧饱和度恢复,BFI和皮肤血流逐渐恢复,提示DCS可连续监测微循环复苏。
- VA-ECMO流量从100降至30 mL·kg⁻¹·min⁻¹时,MAP从64.7(62.3, 69.9)降至36.4(34.4, 44.6)mmHg,BFI从3.6(3.4, 5.1)降至1.0(0.8, 1.2)×10⁻⁹·cm²·s⁻¹。
- 使用血管收缩药后MAP升至83.1(79.0, 89.1)mmHg,但BFI仅1.5(1.3, 2.1)×10⁻⁹·cm²·s⁻¹,未能改善,提示大循环改善不一定伴随微循环改善。
- 作者认为DCS可能有助于心源性休克及VA-ECMO支持期间早期识别微循环障碍并优化治疗。
适用人群与场景
- 研究人群为7只雄性比格犬(中位体重10.1 kg),经冠状动脉结扎诱导心源性休克后诱发心室颤动并接受VA-ECMO支持。
处置流程与药物剂量
- VA-ECMO在室颤发生后5分钟启动,流量80-100 mL·kg⁻¹·min⁻¹,非搏动血流维持90分钟。
- 稳定后将VA-ECMO流量从100降至30 mL·kg⁻¹·min⁻¹,并使用血管收缩药将平均动脉压升至≥65 mmHg。
研究设计与关键结果
- 动物实验:7只雄性比格犬,冠状动脉结扎诱导心源性休克后诱发室颤,5分钟后启动VA-ECMO(80-100 mL·kg⁻¹·min⁻¹)并维持90分钟非搏动血流。
- 基线MAP中位数109.6(95.8, 119.7)mmHg,心源性休克发生时降至45.7(26.3, 51.6)mmHg。
- 室颤期间灌注指数无法测量,BFI快速降至近零,检测到非搏动条件下的外周血流丧失。
- VA-ECMO启动恢复MAP和混合静脉血氧饱和度,BFI和皮肤血流逐渐恢复。
- VA-ECMO流量从100降至30 mL·kg⁻¹·min⁻¹后,MAP从64.7(62.3, 69.9)降至36.4(34.4, 44.6)mmHg,BFI从3.6(3.4, 5.1)降至1.0(0.8, 1.2)×10⁻⁹·cm²·s⁻¹。
- 使用血管收缩药后MAP升至83.1(79.0, 89.1)mmHg,但BFI为1.5(1.3, 2.1)×10⁻⁹·cm²·s⁻¹,未见改善,提示持续微循环障碍。
证据类型、等级与局限
- 证据类型:动物实验研究(比格犬心源性休克及VA-ECMO模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为DCS可能有助于心源性休克及VA-ECMO支持期间早期识别微循环障碍并优化治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: In cardiogenic shock (CS), persistent microcirculatory impairment despite improved macrocirculatory parameters is associated with poor outcomes. Therapeutic strategies must therefore address both macro- and microcirculation. Conventional microcirculatory measures have limitations, especially during venoarterial extracorporeal membrane oxygenation support (VA-ECMO). Diffuse correlation spectroscopy (DCS) is a novel optical technique enabling continuous, noninvasive evaluation of microvascular blood flow. This study evaluated DCS for monitoring microcirculation in CS under VA-ECMO.
METHODS: Seven male beagle dogs (median weight 10.1 kg) underwent CS induction by coronary ligation followed by ventricular fibrillation (VF). VA-ECMO (80-100 mL·kg -1 ·min -1 ) was initiated 5 minutes after VF onset and maintained for 90 minutes under nonpulsatile flow. After stabilization, VA-ECMO flow was reduced from 100 to 30 mL·kg -1 ·min -1 , and mean arterial pressure (MAP) was increased to ≥65 mmHg using vasoconstrictors. Measurements included MAP, cardiac output, and microcirculatory parameters [DCS-derived blood flow index (BFI), perfusion index, skin blood flow, tissue oxygen saturation, mixed venous oxygen saturation, and lactate].
RESULTS: Coronary ligation caused progressive declines in MAP, cardiac output, and microcirculatory indices. MAP [median (interquartile range)] was 109.6 (95.8, 119.7) at baseline and 45.7 (26.3, 51.6) mmHg at CS onset. During VF, perfusion index became unmeasurable while BFI rapidly fell to near zero, detecting peripheral flow loss under nonpulsatile conditions. VA-ECMO initiation restored MAP and mixed venous oxygen saturation, with gradual recovery of BFI and skin blood flow. Reducing VA-ECMO flow lowered MAP [64.7 (62.3, 69.9) to 36.4 (34.4, 44.6) mmHg] and BFI [3.6 (3.4, 5.1) to 1.0 (0.8, 1.2) × 10 -9 ·cm 2 ·s -1 ]. Vasopressors increased MAP [83.1 (79.0, 89.1) mmHg] but failed to improve BFI [1.5 (1.3, 2.1) × 10 -9 ·cm 2 ·s -1 ], indicating persistent microcirculatory impairment.
CONCLUSIONS: DCS continuously detected microvascular changes during CS and VA-ECMO support regardless of pulsatility. DCS may be useful for early identification of microcirculatory dysfunction and optimization of therapy in CS.
参考来源
- Matsushita H, Ohba K, Kurono K, et al. Diffuse Correlation Spectroscopy for Noninvasive Monitoring of Peripheral Perfusion During Cardiogenic Shock and VA-ECMO Support: An Experimental Study. Shock. 2026. PMID: 41886366. doi:10.1097/SHK.0000000000002842
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。